Oleclumab
Phase 3Monoclonal antibody
AstraZenecaOleclumab is an experimental drug being tested to treat certain types of cancer by helping the immune system recognize and attack cancer cells.[1] Oleclumab is currently being investigated across 10 indications[3], with its most advanced program in Phase 3.[1]
Oleclumab is one of 291 small molecule programs targeting Metastatic Angiosarcoma. It is currently in Phase 3.
10
Indications
23
Total Trials
14
Active Trials
290
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Oleclumab
AstraZenecaPhase 3
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Lexiscan
AstellasPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer7 trials
Show 4 more trials
Advanced Solid Tumors2 trials
11 more indications
Durvalumab1 trial
Phase II1 trial
Pancreatic Cancer1 trial
Breast Cancer1 trial
Bladder Cancer1 trial
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Completed·—·Phase 1·NCT03773666·12 enrolled
Colorectal Carcinoma1 trial
Triple Negative Breast Neoplasms1 trial
Carcinoma, Non-Small-Cell Lung1 trial
Pancreatic Ductal Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oleclumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- 5'-Nucleotidase Inhibitor[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company